Lionel Galicier

Lionel Galicier

Auto-generated profile, based on publicly available information

Lionel Galicier

National Reference Center for Castleman disease, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JFJehane Fadlallah
Jehane Fadlallah
HKHela El Kafsi
Hela El Kafsi
DSDelphine Sterlin
Delphine Sterlin
CJCatherine Juste
Catherine Juste
CPChristophe Parizot
Christophe Parizot
GGGuy Gorochov
Guy Gorochov
IgA influences bacterial fitness in the intestinal lumen and is only partially compensated for by IgM in selective IgA-deficient patients.

11 February 2021 in Blood
Verified
Journal Article
Open access
PDF file
PCPaul Coppo*
Paul Coppo*
MBMichael Bubenheim
Michael Bubenheim
EAElie Azoulay
Elie Azoulay
LGLionel Galicier
Lionel Galicier
SMSandrine Malot
Sandrine Malot
YBYgal Benhamou
Ygal Benhamou
The anti–von Willebrand factor nanobody caplacizumab was licensed for adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on prospective controlled trials. However, few data are available on postmarketing surveillance. We treated 90 iTTP patients with a compassionate frontline triplet regimen associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab. Outcomes were compared with 180 historical patients treated with the standard frontline treatment (TPE and corticosteroids, with rituximab as salvage therapy). The primary outcome was a composite of refractoriness and death within 30 days since diagnosis. Key secondary outcomes were exacerbations, time to platelet count recovery, the number of TPE, and the volume of plasma required to achieve durable remission. The percentage of patients in the triplet regimen with the composite primary outcome was 2.2% vs 12.2% in historical patients (P = .01). One elderly patient in the triplet regimen died of pulmonary embolism. Patients from this cohort experienced less exacerbations (3.4% vs 44%, P < .01); they recovered durable platelet count 1.8 times faster than historical patients (95% confidence interval, 1.41-2.36; P < .01), with fewer TPE sessions and lower plasma volumes (P < .01 both). The number of days in hospital was 41% lower in the triplet regimen than in the historical cohort (13 vs 22 days; P < .01). Caplacizumab-related adverse events occurred in 46 patients (51%), including 13 major or clinically relevant nonmajor hemorrhagic events. Associating caplacizumab to TPE and immunosuppression, by addressing the 3 processes of iTTP pathophysiology, prevents unfavorable outcomes and alleviates the burden of care.

17 July 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
MMMatthieu Mahévas
Matthieu Mahévas
GMGuillaume Moulis
Guillaume Moulis
EAEmmanuel Andres
Emmanuel Andres
EREtienne Riviere
Etienne Riviere
MGMargaux Garzaro
Margaux Garzaro
BGBertrand Godeau
Bertrand Godeau
The causes of secondary immune thrombocytopenia (ITP), which account for approximately 18 to 20% of all adult ITP cases, include some viral infections (Cines et al , 2009; Moulis et al , 2014). Indeed, ITP can be triggered by or associated with many viruses including hepatitis C virus, human immunodeficiency virus, cytomegalovirus, Epstein‐Barr virus and others like severe acute respiratory syndrome coronavirus 1 (SARS‐CoV‐1) (Boyer Chammard et al , 2017; Tanaka et al , 2003; Yang et al , 2005; Cines et al , 2009). Among the suspected mechanisms, antibodies directed against virus glycoproteins may cross‐react with platelet surface integrins like GPIIb/IIIa or GPIb‐IX‐V (Assinger, 2014).

23 April 2019 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
DBDavid Boutboul
David Boutboul
JFJehane Fadlallah
Jehane Fadlallah
SCSylvain Chawki
Sylvain Chawki
CFClaire Fieschi
Claire Fieschi
MMMarion Malphettes
Marion Malphettes
LGLionel Galicier
Lionel Galicier

12 December 2019 in Blood
Verified
Journal Article
Closed access
RPRenaud Prevel
Renaud Prevel
CBClaire Roubaud Baudron
Claire Roubaud Baudron
SGSamuel Gourlain
Samuel Gourlain
MJMatthieu Jamme
Matthieu Jamme
KPKarine Peres
Karine Peres
PCPaul Coppo
Paul Coppo
Prevel and colleagues examined the natural history of thrombotic thrombocytopenic purpura (TTP) in older adults, reporting that the geriatric TTP population experiences delayed diagnosis and more severe neurologic and renal impairment. Older patients also have greater short- and long-term mortality.

18 August 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
BFBenjamin Fournier
Benjamin Fournier
DBDavid Boutboul
David Boutboul
JBJulie Bruneau
Julie Bruneau
CMCharline Miot
Charline Miot
CBCécile Boulanger
Cécile Boulanger
SLSylvain Latour
Sylvain Latour
Epstein-Barr virus (EBV) preferentially infects epithelial cells and B lymphocytes and sometimes T and NK lymphocytes. Persistence of EBV-infected cells results in severe lymphoproliferative disorders (LPDs). Diagnosis of EBV-driven T or NK cell LPD and chronic active EBV diseases (CAEBV) is difficult, often requiring biopsies. Herein, we report a flow-FISH cytometry assay that detects cells expressing EBV-encoded small RNAs (EBERs), allowing rapid identification of EBV-infected cells among PBMCs. EBV-infected B, T, and/or NK cells were detectable in various LPD conditions. Diagnosis of CAEBV in 22 patients of Caucasian and African origins was established. All exhibited circulating EBV-infected T and/or NK cells, highlighting that CAEBV is not restricted to native American and Asian populations. Proportions of EBV-infected cells correlated with blood EBV loads. We showed that EBV-infected T cells had an effector memory activated phenotype, whereas EBV-infected B cells expressed plasma cell differentiation markers. Thus, this method achieves accurate and unambiguous diagnoses of different forms of EBV-driven LPD and represents a powerful tool to study their pathophysiological mechanisms.